-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cholestatic diseases, such as primary or secondary sclerosing cholangitis (PSC, SSC) and primary cholangitis (PBC), can cause skin itching, and severe cases can significantly reduce the patient’s quality of life
The results of a double-blind, randomized, placebo-controlled trial (FITCH trial) published in Gastroenterology showed that bezafibrate can effectively relieve pruritus in patients with PSC, PBC, and SSC
Between 2016 and 2019, the study recruited 74 patients with moderate to severe itching caused by PSC, PBC, or SSC (visual analog scale [VAS] ≥ 5 points)
In the end, 70 people completed the trial (95%; 44 PSC, 24 PBC, 2 SSC)
For the primary endpoint, 45% of patients in the bezafibrate group (41% PSC, 55% PBC) and 11% of patients in the placebo group had a reduction of ≥50% in severe or moderate pruritus
In addition, bezafibrate also reduced the level of serum alkaline phosphatase (-35%, P = .
Bezafibrate also reduced the level of serum alkaline phosphatase (-35%, P = .
In summary, the results of this randomized placebo-controlled trial confirm that bezafibrate can effectively improve moderate to severe skin itching in patients with PSC and PBC
Original source:
Elsemieke de Vries, et al.
Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial
in this message